Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALERT topical therapy regression test study in atopic dermatitis–predisposed patients
2009-012194-35Phase 4Completed
- Sponsor
- bioskin
- Start
- Oct 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of pimecrolimus, hydrocortisone, triamcinolone acetonide and betamethasone in atopic dermatitis (AD) (5 arms), sponsored by bioskin. Started Oct 2009; status: completed.
02
Drugs
pimecrolimushydrocortisonetriamcinolone acetonidebetamethasone
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2009-012194-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012194-35.